Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

71%

5 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4

3(42.9%)

Phase 2

2(28.6%)

Phase 3

2(28.6%)

7Total

Phase 4(3)

Phase 2(2)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07406217Phase 2Recruiting

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients

Role: lead

NCT05575830Phase 4Active Not Recruiting

Immune Response of Shingrix Vaccine in People Living With HIV (> 50 y.o.) Compared to Age-matched Controls

Role: lead

NCT04364022Phase 3Completed

Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland

Role: lead

NCT01683656Phase 4Terminated

ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART

Role: lead

NCT03160105Phase 4Completed

Evaluation of a Simplified Strategy for the Long-term Management of HIV Infection (Simpl'HIV)

Role: lead

NCT02572947Phase 2Completed

A Pilot Study of MONOtherapy of DOlutegravir in HIV-1 Virologically Suppressed Patients

Role: lead

NCT01543035Phase 3Completed

Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs

Role: lead

All 7 trials loaded